

CLEAN VERSION OF AMENDMENTS

Amend claims 4-7 as follows:

4. (amended) A compound of formula I as defined in claim 1 including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl and the compound of formula II as defined in claim 1 for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.
5. (amended) A compound of formula I as defined in claim 1 including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl and the compound of formula II as defined in claim 1 as a combined preparation for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.
6. (amended) A product containing a compound of formula I as defined in claim 1 including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl and the compound of formula II as defined in claim 1 as combined preparation for simultaneous, separate, or sequential use for the treatment of co-morbid conditions associated with obesity,
7. (amended) A process of manufacturing a medicament for the treatment of co-morbid conditions associated with obesity in a patient who is also receiving treatment with orlistat comprising the step of incorporating into said medicament an effective amount of a compound of formula I including enantiomers and pharmaceutically

A1 acceptable salts thereof, in which R_1 and R_2 are independently H or methyl.
